Log in

NASDAQ:YTENYield10 Bioscience Stock Price, Forecast & News

-0.04 (-0.64 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $6.23
50-Day Range
MA: $6.34
52-Week Range
Now: $6.23
Volume1,812 shs
Average Volume68,379 shs
Market Capitalization$12.27 million
P/E RatioN/A
Dividend YieldN/A
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was founded in 1992 and is headquartered in Woburn, Massachusetts.
Read More
Yield10 Bioscience logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars

Industry, Sector and Symbol

Industry Miscellaneous plastics products
Current SymbolNASDAQ:YTEN



Sales & Book Value

Annual Sales$810,000.00
Book Value($4.38) per share


Net Income$-12,960,000.00
Net Margins-1,660.40%


Market Cap$12.27 million
Next Earnings Date8/11/2020 (Confirmed)
OptionableNot Optionable
-0.04 (-0.64 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive YTEN News and Ratings via Email

Sign-up to receive the latest news and ratings for YTEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Yield10 Bioscience (NASDAQ:YTEN) Frequently Asked Questions

How has Yield10 Bioscience's stock been impacted by COVID-19 (Coronavirus)?

Yield10 Bioscience's stock was trading at $4.82 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, YTEN stock has increased by 29.3% and is now trading at $6.23.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Yield10 Bioscience?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Yield10 Bioscience in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Yield10 Bioscience

When is Yield10 Bioscience's next earnings date?

Yield10 Bioscience is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Yield10 Bioscience

How can I listen to Yield10 Bioscience's earnings call?

Yield10 Bioscience will be holding an earnings conference call on Tuesday, August 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Yield10 Bioscience's earnings last quarter?

Yield10 Bioscience Inc (NASDAQ:YTEN) announced its quarterly earnings data on Thursday, May, 14th. The specialty chemicals company reported ($2.12) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.97) by $0.15. The specialty chemicals company earned $0.18 million during the quarter. Yield10 Bioscience had a negative net margin of 1,660.40% and a negative return on equity of 464.23%.
View Yield10 Bioscience's earnings history

When did Yield10 Bioscience's stock split? How did Yield10 Bioscience's stock split work?

Yield10 Bioscience's stock reverse split on the morning of Thursday, January 16th 2020. The 1-40 reverse split was announced on Wednesday, January 15th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 15th 2020. An investor that had 100 shares of Yield10 Bioscience stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for YTEN?

3 Wall Street analysts have issued 1-year price objectives for Yield10 Bioscience's stock. Their forecasts range from $10.00 to $80.00. On average, they anticipate Yield10 Bioscience's stock price to reach $35.50 in the next twelve months. This suggests a possible upside of 469.8% from the stock's current price.
View analysts' price targets for Yield10 Bioscience

What are Wall Street analysts saying about Yield10 Bioscience stock?

Here are some recent quotes from research analysts about Yield10 Bioscience stock:
  • 1. According to Zacks Investment Research, "Yield10 Bioscience, Inc. is an agricultural bioscience company. It focuses on the development of disruptive technologies for improvement in crop yield to enhance global food security. The company is working on new approaches, to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism for better production. It operates primarily in Saskatoon, Saskatchewan, Canada. Yield10 Bioscience, Inc., formerly known as Metabolix, Inc., is based in Woburn, Massachusetts. " (7/4/2020)
  • 2. National Securities analysts commented, " Additional Genes Now Under Consideration. The research license with Bayer (STU: BAY – NR - €66.48) has been amended to include an expanded scope for the C3004 trait. Under the original agreement signed in late 2017, BAY considered the C3003 and C3004 traits for evaluation in soybean, with the genes under consideration targeted to controlling carbon flow. With YTEN’s additional discoveries in the C3004 trait from 2018 trials in camelina, the research license was expanded to include a broader scope of genes.
     A Validation Of Technology? We expect that since the December 2017 license was signed that BAY has studied the C3003 and C3004 traits within its soybean varieties in greenhouse settings, and moved to field trials in Spring 2019. We believe that BAY could easily terminate the agreement if it saw no commercial potential, and we believe the expanded scope represents a validation of YTEN technology.
     No Better Commercial Partner. Following BAY’s acquisition of Monsanto, it controls roughly one third of global soybean sales, and its overall market share is significantly greater when considering seed distributed by peers which include BAY licensed traits. We believe of the major commercial crops that there is no better partner for YTEN than BAY and its soybean market.
     Additional Agreements Needed, May Come With Funded R&D. We anticipate that YTEN is in active discussions with other commercial partners and believe future research agreements may come with a funded R&D component." (8/20/2019)

Has Yield10 Bioscience been receiving favorable news coverage?

Media stories about YTEN stock have been trending very negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Yield10 Bioscience earned a media sentiment score of -3.4 on InfoTrie's scale. They also assigned press coverage about the specialty chemicals company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Yield10 Bioscience

Are investors shorting Yield10 Bioscience?

Yield10 Bioscience saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 64,200 shares, an increase of 15.5% from the July 15th total of 55,600 shares. Based on an average trading volume of 703,700 shares, the days-to-cover ratio is currently 0.1 days. Approximately 4.2% of the company's shares are short sold.
View Yield10 Bioscience's Short Interest

Who are some of Yield10 Bioscience's key competitors?

What other stocks do shareholders of Yield10 Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Yield10 Bioscience investors own include KushCo (KSHB), Canopy Growth (CGC), NovaBay Pharmaceuticals (NBY), FuelCell Energy (FCEL), Onconova Therapeutics (ONTX), Advanced Micro Devices (AMD), (CHK), Rigel Pharmaceuticals (RIGL), Arcadia Biosciences (RKDA) and Viking Therapeutics (VKTX).

Who are Yield10 Bioscience's key executives?

Yield10 Bioscience's management team includes the following people:
  • Dr. Oliver P. Peoples, Co-Founder, Pres, CEO & Director (Age 61)
  • Dr. Anthony J. Sinskey, Co-Founder & Director (Age 79)
  • Dr. Kristi Snell, VP of Research & Chief Science Officer (Age 51)
  • Ms. Lynne H. Brum, VP of Planning & Communications and Sec. (Age 55)
  • Mr. Charles B. Haaser, VP of Fin., Chief Accounting Officer & Treasurer (Age 63)

What is Yield10 Bioscience's stock symbol?

Yield10 Bioscience trades on the NASDAQ under the ticker symbol "YTEN."

Who are Yield10 Bioscience's major shareholders?

Yield10 Bioscience's stock is owned by many different retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.52%). Company insiders that own Yield10 Bioscience stock include Jack W Schuler and Oliver P Peoples.
View institutional ownership trends for Yield10 Bioscience

Which institutional investors are buying Yield10 Bioscience stock?

YTEN stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Yield10 Bioscience stock in the last two years include Jack W Schuler, and Oliver P Peoples.
View insider buying and selling activity for Yield10 Bioscience

How do I buy shares of Yield10 Bioscience?

Shares of YTEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Yield10 Bioscience's stock price today?

One share of YTEN stock can currently be purchased for approximately $6.23.

How big of a company is Yield10 Bioscience?

Yield10 Bioscience has a market capitalization of $12.27 million and generates $810,000.00 in revenue each year. The specialty chemicals company earns $-12,960,000.00 in net income (profit) each year or ($35.50) on an earnings per share basis. Yield10 Bioscience employs 22 workers across the globe.

What is Yield10 Bioscience's official website?

The official website for Yield10 Bioscience is www.yield10bio.com.

How can I contact Yield10 Bioscience?

Yield10 Bioscience's mailing address is 19 PRESIDENTIAL WAY, WOBURN MA, 01801. The specialty chemicals company can be reached via phone at 617-583-1700 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.